NICE recommends ixekizumab for persistent severe plaque psoriasis

Click for article

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

Advertisements

End of life care for infants, children and young people with life limiting conditions: summary of NICE guidance

Click for article

Click for article

Children and young people can have a wide range of life limiting conditions and may sometimes live with such conditions for many years. This guideline recommends that end of life care be managed as a long term process that begins at the time of diagnosis of a life limiting condition and entails planning for the future. Sometimes it may begin before the child’s birth. It is part of the overall care of the child or young person and runs in parallel with other active treatments for the underlying condition itself. Finally, it includes those aspects related to the care of the dying.

NICE recommends dropping two drugs from Cancer Drugs Fund

Click for article

Click for article

Two drugs currently provided under the Cancer Drugs Fund (CDF) should cease to be available because they are not cost effective, the National Institute for Health and Care Excellence (NICE) has concluded.

Everolimus for breast cancer (Afinitor, Novartis) and ibrutinib for mantle cell lymphoma (Imbruvica, Janssen) do not meet the grade, says NICE in draft guidance now open for consultation.Nice_logo

Suspected sepsis: summary of NICE guidance

nice_logoGuidelines include:

  • “Think sepsis” in any person with suspected infection

  • Sepsis may present with non-specific symptoms and signs and without fever

  • Have a high index of suspicion of sepsis in those who are aged <1 year or >75 years, pregnant, or immunocompromised, and those who have a device or line in situ or have had recent surgery

  • Use risk factors and any indicators of clinical concern to decide if full assessment is required

  • Offer people at high risk of sepsis broad spectrum antibiotics and intravenous fluids in hospital

Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance

Click for article

Click for article

Coeliac disease is a common autoimmune condition, in which the ingestion of gluten (present in wheat, barley, and rye) activates an abnormal immune response, leading to chronic inflammation of the small intestine and malabsorption of nutrients. It affects about 1% of the UK population.

NICE recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness.

2015 Heatwave Plan for England

The 2015 Heatwave Plan for England has now taken effect, and the Met Office will be issuing Heatwave Alerts from 1 June to 15 September 2015.

Click image for article

Click image for article

The Heatwave plan for England remains a central part of the Department of Health’s support to the NHS, social care and local authorities, providing guidance on how to prepare for and respond to a heatwave which can affect everybody’s health, but particularly the most vulnerable people in society.